Huang et al., 2020 - Google Patents
Narcolepsy and 2009 H1N1 pandemic vaccination in TaiwanHuang et al., 2020
- Document ID
- 4283606368267346808
- Author
- Huang W
- Huang Y
- Hsu C
- Chen H
- Lee H
- Lin H
- Hsieh C
- Wu M
- Yang C
- Publication year
- Publication venue
- Sleep medicine
External Links
Snippet
Abstract Background Several European countries have observed an association between narcolepsy and H1N1 vaccines containing AS03® adjuvant in children/adolescents. In Taiwan, a nationwide campaign starting November 2009 administered H1N1 vaccines …
- 201000003631 narcolepsy 0 title abstract description 92
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/327—Management of hospital data, e.g. scheduling of medical staff or operation rooms, measuring the quality or efficiency of medical staff
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
- G06Q50/24—Patient record management
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan | |
| Chodick et al. | The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence | |
| Fadlyana et al. | A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia | |
| Geng et al. | Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial | |
| Beaulieu et al. | Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines | |
| Jaca et al. | A systematic review of strategies for reducing missed opportunities for vaccination | |
| Sun et al. | Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B | |
| Offit et al. | Communicating science to the public: MMR vaccine and autism | |
| Langer-Gould et al. | Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases | |
| Talbot et al. | The safety of immunizing with tetanus–diphtheria–acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak | |
| Halsey et al. | Algorithm to assess causality after individual adverse events following immunizations | |
| Wiemken et al. | Comparison of rates of dementia among older adult recipients of two, one, or no vaccinations | |
| Becerra-Culqui et al. | Prenatal tetanus, diphtheria, acellular pertussis vaccination and autism spectrum disorder | |
| Huang et al. | Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study | |
| Reusch et al. | Influencing factors of anti‐SARS‐CoV‐2‐spike‐IgG antibody titers in healthcare workers: A cross‐section study | |
| Chen et al. | Vaccines and the risk of acute disseminated encephalomyelitis | |
| Shibata et al. | Effectiveness of influenza vaccination for children in Japan: four-year observational study using a large-scale claims database | |
| Kashangura et al. | MVA85A vaccine to enhance BCG for preventing tuberculosis | |
| Manley et al. | SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients | |
| Tian et al. | Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study | |
| Yen et al. | Risk of Guillain-Barré syndrome among older adults receiving influenza vaccine in Taiwan | |
| Chemaitelly et al. | Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar | |
| Ku et al. | Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study | |
| Clemens et al. | Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil | |
| Burns et al. | Antibody response to vaccination as a marker of in vivo immune function in psychophysiological research |